Based on news reporting.
Intercept Pharmaceuticals has announced a restructuring that will result in 146 layoffs, following the withdrawal of its drug Ocaliva. This decision comes as the company seeks to realign its operations after the setback with Ocaliva, which has impacted its business strategy. The layoffs are part of a broader effort to streamline the organization and focus on future growth opportunities. The exact locations and departments affected by these layoffs have not been disclosed. This move reflects the challenges faced by Intercept in the current pharmaceutical landscape.
Intercept Pharmaceuticals cut 146 jobs as of October 1, 2023.
That is roughly 73% of the 200 people Intercept Pharmaceuticals employs.
LayoffTalk has tracked 3 layoff events at Intercept Pharmaceuticals since October 2023, affecting a combined 438 employees.
Anonymous by default. Be kind — people reading this may be going through it right now.
No comments yet. Be the first to share your thoughts.
Share your story anonymously — it helps others reading this feel less alone.
Share your story →Recent tracked events at this company.